Releases
Vector Science & Therapeutics Targets August Revenue After Going Public
Following its April reverse takeover, Vector Science & Therapeutics has filed its inaugural quarterly financial report, signaling a transition toward commercial operations. The Mequon-based firm expects to begin generating revenue from its peptide manufacturing division in August, while advancing its lead pain management technology toward federal regulatory approval.






















